US 2003/0153063 A1Published application

Novel human G-protein coupled receptor, HGPRBMY11, expressed highly in heart and variants thereof

OwnerJohn N. Feder, Thomas C. Nelson +3inventors

InventorsJohn N. Feder, Thomas C. Nelson, Chandra S. Ramanathan, Angela M. Cacace, Lauren E. Barber

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present invention provides novel polynucleotides encoding HGPRBMY11 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of the HGPRBMY11 polypeptide, HGPRBMY11v1 and HGPRBMY11v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY11, HGPRBMY11v1, and/or HGPRBMY11v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly cardiovascular diseases and/or disorders. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

Claims41

Dependent claims

An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polynucleotide fragment of SEQ ID NO:1 or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:PTA-2766, which is hybridizable to SEQ ID NO:1;
(b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:2 or a polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:
PTA-2766, which is hybridizable to SEQ ID NO:1;
(c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:2 or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:
PTA-2766, which is hybridizable to SEQ ID NO:1;
(d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:2 or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:
PTA-2766, which is hybridizable to SEQ ID NO:1;
(e) a polynucleotide encoding a polypeptide of SEQ ID NO:2 or the cDNA sequence included in ATCC Deposit No:
PTA-2766, which is hybridizable to SEQ ID NO:1, having biological activity;
(f) a polynucleotide which is a variant of SEQ ID NO:1;
(g) a polynucleotide which is an allelic variant of SEQ ID NO:1;
(h) an isolated polynucleotide comprising nucleotides 518 to 1504 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 minus the start codon;
(i) an isolated polynucleotide comprising nucleotides 515 to 1504 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 including the start codon;
(j) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:1;
and
(k) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(j), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

13 more elements

An isolated nucleic acid molecule consisting of a polynucleotide having a nucleotide sequence selected from the group consisting of:

(a) a polynucleotide encoding a polypeptide of SEQ ID NO:2;
(b) a polynucleotide comprising nucleotides 518 to 1504 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 minus the start codon;
(c) a polynucleotide comprising nucleotides 515 to 1504 of SEQ ID NO:1, wherein said nucleotides encode a polypeptide of SEQ ID NO:2 including the start codon;
(d) a polynucleotide encoding the HGPRBMY11 polypeptide encoded by the cDNA clone contained in ATCC Deposit No. PTA-2766;
(e) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:1;
(f) a polynucleotide encoding a polypeptide of SEQ ID NO:30;
(g) a polynucleotide comprising nucleotides 4 to 1038 of SEQ ID NO:29, wherein said nucleotides encode a polypeptide of SEQ ID NO:30 minus the start codon;
(h) a polynucleotide comprising nucleotides 1 to 1038 of SEQ ID NO:29, wherein said nucleotides encode a polypeptide of SEQ ID NO:30 including the start codon;
(i) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:29;
(j) a polynucleotide encoding a polypeptide of SEQ ID NO:55;
(k) a polynucleotide comprising nucleotides 4 to 1023 of SEQ ID NO:54, wherein said nucleotides encode a polypeptide of SEQ ID NO:55 minus the start codon;
(l) a polynucleotide comprising nucleotides 1 to 1023 of SEQ ID NO:54, wherein said nucleotides encode a polypeptide of SEQ ID NO:55 including the start codon;
and
(m) a polynucleotide which represents the complimentary sequence (antisense) of SEQ ID NO:54.

11 more elements

An isolated polypeptide consisting of an amino acid sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:2 having G-protein coupled receptor activity;
(b) a polypeptide domain of SEQ ID NO:2 having G-protein coupled receptor activity;
(c) a full length protein of SEQ ID NO:2;
(d) a polypeptide corresponding to amino acids 2 to 330 of SEQ ID NO:2, wherein said amino acids 2 to 330 comprise a polypeptide of SEQ ID NO:2 minus the start methionine;
(e) a polypeptide corresponding to amino acids 1 to 330 of SEQ ID NO:2;
(f) a polypeptide encoded by the CDNA contained in ATCC Deposit No. PTA-2766.
(g) a polypeptide fragment of SEQ ID NO:30 having G-protein coupled receptor activity;
(h) a polypeptide domain of SEQ ID NO:30 having G-protein coupled receptor activity;
(i) a full length protein of SEQ ID NO:30;
(j) a polypeptide corresponding to amino acids 2 to 346 of SEQ ID NO:30, wherein said amino acids 2 to 346 comprise a polypeptide of SEQ ID NO:30 minus the start methionine;
(k) a polypeptide corresponding to amino acids 1 to 346 of SEQ ID NO:30;
(l) a polypeptide fragment of SEQ ID NO:55 having G-protein coupled receptor activity;
(m) a polypeptide domain of SEQ ID NO:55 having G-protein coupled receptor activity;
(n) a full length protein of SEQ ID NO:55;
(o) a polypeptide corresponding to amino acids 2 to 341 of SEQ ID NO:55, wherein said amino acids 2 to 341 comprise a polypeptide of SEQ ID NO:55 minus the start methionine;
and
(p) a polypeptide corresponding to amino acids 1 to 341 of SEQ ID NO:55.

14 more elements

Dependencies are inferred from the claim text.

Facts

Application: 09/991,225Filed 16 Nov 2001
Priority: 17 Nov 2000
Published: 14 Aug 2003
Term ends: Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07K 16/28
Against material from animals or humans: against receptors, cell surface antigens or cell surface determinants
A61P 9/00
Drugs for disorders of the cardiovascular system
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00
C07K 14/705
From animals; from humans: receptors; Cell surface antigens; Cell surface determinants